Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 14/20 | 0.57 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.57 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.57 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.57 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.44 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2779763 | 0.95 | GRIA2 (0.64) | GRIA2GRIA1GRIA3GRIA4ABCC8 | |
| SCHEMBL2774118 | 0.86 | GRIA2 (0.65) | GRIA2GRIA1GRIA3GRIA4ABCC8 | |
| SCHEMBL2775051 | 0.76 | GRIA2 (0.89) | GRIA2GRIA1GRIA3GRIA4CA12 | |
| SCHEMBL5625624 | 0.75 | ALDH1A1 (0.59) | ABCC8KCNJ11SIRT2CA12CA9 | |
| SCHEMBL2775552 | 0.73 | GRIA2 (0.70) | GRIA2GRIA1GRIA3GRIA4 | |
| SCHEMBL2774098 | 0.73 | GRIA2 (0.70) | GRIA2GRIA1GRIA3GRIA4 | |
| SCHEMBL2776117 | 0.73 | GRIA2 (0.62) | GRIA2GRIA1GRIA3GRIA4 | |
| SCHEMBL2774819 | 0.73 | GRIA2 (0.79) | GRIA2GRIA1GRIA3GRIA4 | |
| SCHEMBL2779104 | 0.73 | GRIA2 (1.00) | GRIA2GRIA1GRIA3GRIA4 | |
| SCHEMBL5355755 | 0.72 | GRIA2 (0.65) | GRIA2GRIA1GRIA3GRIA4CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2147915-B1 | New cycloalkylated benzothiadiazine derivatives, method of preparing same and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2010-09-15 | — | — | EP | disclosed |
| US-7741320-B2 | Cycloalkylated benzothiadiazines, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2010-06-22 | — | — | US | disclosed |
| EP-2147915-A1 | New cycloalkylated benzothiadiazine derivatives, method of preparing same and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2010-01-27 | — | — | EP | disclosed |
| US-20100009974-A1 | Cycloalkylated benzothiadiazines, a process for their preparation and pharmaceutical compostions containing them | LES LABORATOIRES SERVIER (FR) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009974-A1 | Cycloalkylated benzothiadiazines, a process for their preparation and pharmaceutical compostions containing them | ACLY, HCAR1, GABRG1 | GRIA2 116/4885GRIA1 68/4885GRIA3 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.